Lori Gardner, Senior Director
Membership and Public Relations
301.984.9496 ext. 226
FOR IMMEDIATE RELEASE:
Aug 12, 2021
BACKGROUND: ACCC members provide cancer care in practices and hospitals that are both private and nonprofit and academic and community-based. The diversity of our membership uniquely positions ACCC to effectively engage with policymakers in dialogues about the need for reforms to reduce out-of-pocket costs for prescription drugs and drugs administered in practices, clinics, and hospitals.
ACCC believes that to improve the current treatment options available for patients at the lowest cost without decreasing access to care, the following principles should be taken into consideration:
Any proposed changes in reimbursement for drugs, diagnostics, and biomarker testing should decrease health inequities and not negatively impact the ability of cancer programs and practices to provide necessary supportive care services for potentially disadvantaged patients.
Please visit accc-cancer.org/advocate for additional policy and advocacy information for the cancer care community.
Request: As Congress, the Health Resources & Services Administration (HRSA), and the Centers for Medicare & Medicaid Services (CMS) work to consider reforms to drug pricing and consider changes to the reimbursement of diagnostics and biomarker testing, the Association of Community Cancer Centers requests that no proposed, modeled, or implemented reimbursement plan negatively impact patient access to care and/or the ability of oncology programs and practices to provide quality cancer care to any patient in need, particularly patients from disadvantaged populations in which health disparities can create poor health outcomes.